Image courtesy of Korea Biotechnology Industry Organization
The Korea Biotechnology Industry Organization (KoreaBIO) announced it will host the 5th annual Global IR @JPM 2025 on January 14, 2025, at the Nasdaq Entrepreneurial Center in San Francisco. The event coincides with the J.P. Morgan Healthcare Conference (JPM), the world’s largest healthcare investment conference, from January 13 to 16. Co-hosted by global law firm Sidley Austin LLP and biotech media outlet BioCentury and supported by NASDAQ, the Ministry of Trade, Industry, and Energy, and Biocom California, this year’s event promises to connect promising biotech companies with global investors.
Marking its fifth edition, Global IR @JPM aims to showcase biotech companies’ innovative technologies, enhance their investment appeal, and foster sustainable growth. By providing a platform for IR pitches, the event seeks to highlight company value to professional investors and industry representatives while creating global business networking and collaboration opportunities.
This year, ten select biotech companies will deliver IR presentations. Representing Korea are AbClon, specializing in antibody therapeutics and cell therapy for refractory diseases; Atheon Bio, focusing on next-generation antibody therapies; Cenyx Biotech, which develops cerium oxide nanoparticle-based therapeutics; Mediwhale, an AI platform predicting systemic diseases using fundus imaging; VSPharmTech, which develops radiosensitizers to enhance radiotherapy efficacy; and Novelty Nobility, working on antibody drugs for cancer, immune diseases, and ophthalmic disorders.
International companies include Antabio, from France, which develops antibiotics for resistant bacterial infections; Berlin Heals, from Germany, which creates implantable electrical therapy devices for cardiac tissue regeneration; Calissa Therapeutics, from the U.S., which developed the first drug therapy for port-wine stains; and Interon Laboratories, also from the U.S., which focuses on treatments for autism and neurological disorders.
Following each presentation, a panel of 13 investors, including representatives from JP Morgan, J&J Innovation, Pfizer Ignite, and Korea Investment Partners, will conduct Q&A sessions to evaluate investment potential.
The event also features two panel discussions on global biotech investment and dealmaking trends for 2025. In the Cross-border Investment Outlook 2025 session, moderated by BioCentury’s Jeff Cranmer, André Andonian of Flagship Pioneering, Amit Kakar of Novo Holdings, and Maziar Zarrehparvar of Kurma Partners will discuss cross-border investment trends and growth drivers for the year ahead.
The second session, Insights on Dealmaking Trends, Examination of the NewCo Model, will be chaired by Joshua T. Hofheimer of Sidley Austin and include Ken Song of Candid Therapeutics, Stephan Lensky of EpimAb Biotherapeutics, and Dan Wang of J&J Innovation. They will delve into emerging dealmaking trends amid evolving regulatory landscapes, accelerated AI adoption, increased supply chain complexities, and changing consumer needs.
The 6th annual Korea Night @JPM 2025 networking event will also occur on the evening of January 15. Last year’s event attracted over 500 global investors and corporate leaders, underscoring the worldwide interest in Korea’s biotech industry. This year’s event, supported by 42 Korean biotech companies, has already confirmed participation from over 350 companies and 500 attendees.
Jurie Hwang, Head of International Cooperation at KoreaBIO, emphasized, “Through these events at JPM, we aim to provide Korean companies with insights into global investment and technology trends while showcasing their innovative technologies and vision to global investors and corporations.”
Attendance is limited to pre-registered participants. Further details and registration are available on KoreaBIO’s official website.
